Waltham, Massachusetts (PRWEB) February 13, 2012
Headlining this years OpenClinica Global Conference is Dr. Tomasz Sablinski, a leading clinical research innovator who is challenging the current model of drug development. Dr. Sablinski will talk about how barriers to delivering new medical treatments via clinical development can be overcome by borrowing from contemporary concepts of transparency, crowd sourcing, and open innovation.
Dr. Sablinskis perspective reflects his 30+ years working as a practicing physician, basic researcher, drug developer, investor, and entrepreneur. During this time, has served as a researcher at Harvard Medical School, a Medical Director at Parexel, VP of Clinical Development at Novartis, and Head of Development and Managing Director at private equity firm Celtic Therapeutics.
According to Dr. Sablinski, The emerging clinical development crisis requires a re-thinking of the entire process. Those organizations flexible enough to adapt by redesigning the way clinical trials are conceived and conducted using advances in communications and telemedicine, along with open innovation principles, will, I believe, prevail in the long run.
Dr. Sablinski believes we are at an inflection point–the persistent poor productivity of existing clinical approaches provides a unique opportunity for bringing much- needed innovation to the clinical trials industry.
We are thrilled to have Dr. Tomasz Sablinski deliver the keynote address at this years OpenClinica conference, said Ben Baumann, Chair of the OpenClinica Conference Committee. His bold ideas will be sure to challenge many of our current assumptions in thought-provoking, even controversial ways. He is not afraid to question the status quo, and seeks to encourage much of the same type of disruptive innovation that OpenClinica strives to bring to clinical research.
More information about the 2012 OpenClinica Conference is available online at https://community.openclinica.com/conference.
About the 2012 OpenClinica Conference
